Nutrient Stimulated Hormone Therapies in Obesity Care

Overview

Managing obesity has evolved over time and led to a variety of management approaches. One of the effective treatment modalities is pharmacological interventions, including the use of GLP-1-based medications to address the unique needs of a person living with obesity. Join us for an overview of the current GLP-1-based medications that are currently available and are coming to market. Participants will gain insights into pharmacotherapy for obesity management, including the appropriate use, short-term side effects, and the impact they can have on other complications.

Learning Objectives

By the end of this training, participants should be able to:

Recall and describe the evolution of obesity management approaches and the introduction of GLP-1-based medications currently available and near market approval.
Understand and describe the mechanism of action GLP-1-based medications have on obesity.
Recognize common short-term side effects associated with using GLP-1-based medications.
Identify the positive impact GLP-1-based medications can have on obesity related complications.

Funder Acknowledgment

Novo Nordisk is a strategic supporter of the Obesity Association, a division of the American Diabetes Association.

Summary

Availability:

Registration Required

Location:

Online Meeting

Date / Time:

Sep 17, 2025 4:00 PM - 5:00 PM ET

Cost:

FREE

Credit Offered:

No Credit Offered

Create Account